KR102184154B1 - Composition for anti-oxidation comprising sodium riboflavin 5'-phosphate as an active ingredient - Google Patents
Composition for anti-oxidation comprising sodium riboflavin 5'-phosphate as an active ingredient Download PDFInfo
- Publication number
- KR102184154B1 KR102184154B1 KR1020200040464A KR20200040464A KR102184154B1 KR 102184154 B1 KR102184154 B1 KR 102184154B1 KR 1020200040464 A KR1020200040464 A KR 1020200040464A KR 20200040464 A KR20200040464 A KR 20200040464A KR 102184154 B1 KR102184154 B1 KR 102184154B1
- Authority
- KR
- South Korea
- Prior art keywords
- riboflavin
- skin
- phosphate sodium
- present
- phosphate
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 73
- 239000004480 active ingredient Substances 0.000 title claims description 27
- OHSHFZJLPYLRIP-BMZHGHOISA-M Riboflavin sodium phosphate Chemical compound [Na+].OP(=O)([O-])OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O OHSHFZJLPYLRIP-BMZHGHOISA-M 0.000 title claims description 9
- 230000003064 anti-oxidating effect Effects 0.000 title 1
- 229950001574 riboflavin phosphate Drugs 0.000 claims abstract description 63
- 239000002537 cosmetic Substances 0.000 claims abstract description 29
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 17
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 15
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 235000013376 functional food Nutrition 0.000 claims description 14
- 230000036541 health Effects 0.000 claims description 14
- 239000006071 cream Substances 0.000 claims description 13
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 9
- 239000002151 riboflavin Substances 0.000 claims description 9
- 235000019192 riboflavin Nutrition 0.000 claims description 9
- 229960002477 riboflavin Drugs 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- 239000000839 emulsion Substances 0.000 claims description 6
- 239000000499 gel Substances 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 5
- 239000003921 oil Substances 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 239000000344 soap Substances 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 239000006072 paste Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 230000000475 sunscreen effect Effects 0.000 claims description 2
- 239000000516 sunscreening agent Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 abstract description 63
- 230000037303 wrinkles Effects 0.000 abstract description 27
- 230000006872 improvement Effects 0.000 abstract description 19
- 230000003020 moisturizing effect Effects 0.000 abstract description 19
- 230000037394 skin elasticity Effects 0.000 abstract description 18
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 15
- 210000003491 skin Anatomy 0.000 description 66
- 230000000694 effects Effects 0.000 description 36
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 33
- 229920002674 hyaluronan Polymers 0.000 description 33
- 229960003160 hyaluronic acid Drugs 0.000 description 33
- 108010003272 Hyaluronate lyase Proteins 0.000 description 24
- 102000001974 Hyaluronidases Human genes 0.000 description 24
- 229960002773 hyaluronidase Drugs 0.000 description 24
- 230000002401 inhibitory effect Effects 0.000 description 17
- 238000009472 formulation Methods 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- -1 for example Substances 0.000 description 12
- 235000006708 antioxidants Nutrition 0.000 description 11
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Chinese gallotannin Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 8
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 230000032683 aging Effects 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 230000007423 decrease Effects 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 229920002824 gallotannin Polymers 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 238000007665 sagging Methods 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000011768 flavin mononucleotide Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 210000001626 skin fibroblast Anatomy 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241001340526 Chrysoclista linneella Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 2
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 2
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 2
- 229940013640 flavin mononucleotide Drugs 0.000 description 2
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 2
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- YXJHJCDOUFKMBG-BMZHGHOISA-M riboflavin sodium Chemical compound [Na+].OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)[N-]C2=O YXJHJCDOUFKMBG-BMZHGHOISA-M 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004228 Riboflavin-5'-Phosphate Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003287 riboflavins Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Abstract
본 발명은 리보플라빈 5'-포스페이트 나트륨을 포함하는 화장료 조성물에 관한 것으로서, 보다 구체적으로는 리보플라빈 5'-포스페이트 나트륨을 포함하는 피부 보습용, 피부 탄력 증진 또는 주름 개선용, 항산화용, 또는 항염증용 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition containing riboflavin 5'-phosphate sodium, and more specifically, for skin moisturizing, skin elasticity enhancement or wrinkle improvement, antioxidant, or anti-inflammatory containing riboflavin 5'-phosphate sodium It relates to a cosmetic composition.
Description
본 발명은 리보플라빈 5'-포스페이트 나트륨을 포함하는 화장료 조성물에 관한 것으로서, 보다 구체적으로는 리보플라빈 5'-포스페이트 나트륨을 포함하는 피부 보습용, 피부 탄력 증진 또는 주름 개선용, 항산화용, 또는 항염증용 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition containing riboflavin 5'-phosphate sodium, and more specifically, for skin moisturizing, skin elasticity enhancement or wrinkle improvement, antioxidant, or anti-inflammatory containing riboflavin 5'-phosphate sodium It relates to a cosmetic composition.
노화란 나이가 들면서 신체의 구조와 기능이 점진적으로 저하되고 질병과 사망에 대한 감수성이 급격히 증가하면서 쇠약해지는 과정이다. 피부 노화의 원인은, 거시적으로 보면 가령(加齡)이 중요한 인자이지만, 그것에 더하여 건조, 산화, 태양광(자외선) 등에 의한 영향도 피부 노화에 관한 직접적인 인자로서 들 수 있다. 피부 노화의 구체적인 현상으로서는, 히알루론산을 비롯하는 무코다당류의 감소, 콜라겐의 가교 반응, 자외선에 의한 세포의 손상 등이 알려져 있다.Aging is a process in which the structure and function of the body gradually deteriorate with age and the susceptibility to disease and death rapidly increases, leading to a debilitating process. The cause of skin aging is macroscopically, aging is an important factor, but in addition to it, the effects of dryness, oxidation, sunlight (ultraviolet rays), etc. are also mentioned as direct factors related to skin aging. As specific phenomena of skin aging, reduction of mucopolysaccharides including hyaluronic acid, crosslinking reaction of collagen, and damage to cells due to ultraviolet rays are known.
히알루론산(hyaluronic acid)은 글리코사미노글리칸(glycosaminoglycans)의 일종으로 글루쿠론산과 N-아세틸글루코사민 잔기가 반복적으로 연결되어 있는 사슬모양의 고분자 다당류 물질이다. 다량의 물과 결합하여 겔을 만드는 성질이 있어 높은 점성과 탄성을 가진다. 히알루론산은 세포외 기질 (Extra Cellular Matrix: ECM)의 주요 성분으로, 수분 보유, 세포 간 간격 유지, 세포성장인자 및 영양성분의 저장과 확산에 관여할 뿐만 아니라, 세포의 분열과 분화, 이동 등에도 관여하는 것으로 보고된 바 있다.Hyaluronic acid (hyaluronic acid) is a type of glycosaminoglycans (glycosaminoglycans) is a chain-shaped polymer polysaccharide substance in which glucuronic acid and N-acetylglucosamine residues are repeatedly linked. It combines with a large amount of water to form a gel, so it has high viscosity and elasticity. Hyaluronic acid is a major component of the Extra Cellular Matrix (ECM), and is involved in water retention, maintenance of intercellular spacing, storage and diffusion of cell growth factors and nutrients, as well as cell division, differentiation, and migration. It has also been reported to be involved.
피부에서, 포유류의 체내에 존재하는 히알루론산의 50% 이상이 피부, 특히 표피의 세포 간 간격과 진피의 결체 조직에 분포한다고 보고되었고, 이러한 히알루론산은 주로 각질형성세포와 섬유아세포에 의해 합성되는 것으로 알려져 있다. 인간 피부에서 노화에 의한 히알루론산의 양의 감소는 피부 탄력 저하 및 수분 함유량 감소의 직접적인 원인 중 하나라고 여겨지고 있다(Biochem Biophys Acta 279, 265-275; Carbohydr Res 159, 127-136; Int J Dermatol 33, 119-122). 또한 히알루론산은 각질층의 구조유지와 피부장벽 기능을 유지 하는데에도 관여한다고 알려져 있다(J Cosmet Dermatol. 2007 Jun, 6(2), 75-82). 따라서 히알루론산은 피부 보습에 직접적인 관련이 있다. 이 때문에 노화된 피부의 개선제로서, 히알루론산을 배합한 화장료가 수많이 제안되어 있다.In the skin, it has been reported that more than 50% of the hyaluronic acid present in the mammalian body is distributed in the skin, especially the intercellular spaces of the epidermis and the connective tissues of the dermis, and this hyaluronic acid is mainly synthesized by keratinocytes and fibroblasts. It is known. In human skin, the decrease in the amount of hyaluronic acid due to aging is considered to be one of the direct causes of the decrease in skin elasticity and moisture content (Biochem Biophys Acta 279, 265-275; Carbohydr Res 159, 127-136; Int J Dermatol 33 , 119-122). In addition, hyaluronic acid is known to be involved in maintaining the structure of the stratum corneum and maintaining the skin barrier function (J Cosmet Dermatol. 2007 Jun, 6(2), 75-82). Therefore, hyaluronic acid is directly related to skin moisturizing. For this reason, cosmetics containing hyaluronic acid have been proposed in numerous ways as an improving agent for aged skin.
그러나, 상기와 같은 효과를 가진 히알루론산은 분자량이 커서 피부에 흡수가 잘 되지 않기 때문에 피부 표면에서의 보습 효과를 발휘할 뿐이며, 본질적으로 노화 피부를 개선할 수 있는 것이 아니다. 또한, 히알루론산을 피부 속으로 직접 주입하는 방법이 현재 시술되고 있으나 시간 경과에 따라 효능이 제한적이며 피부 처짐 혹은 만성염증 현상이 있을 수 있으며, 피부 속의 히알루론산량을 상승시키는 물질을 배합한 화장료 조성물도 최근 많이 제안되어 왔지만, 이들도 노화 피부를 명료히 개선시키는 정도까지는 이르지 않는 것이 현재의 상황이다. 히알루론산의 외용 또는 히알루론산의 생성 촉진제의 외용에 의해, 반드시 노화 피부를 명료히 개선할 수 없는 것은, 피부 중에서의 히알루론산의 분해 효소인 히알루로니다아제에 의한 효소 분해가 빠르게 일어나기 때문으로 추측되고 있다. 따라서, 히알루론산 분해를 촉진하는 히알루로니다아제의 활성을 억제하는 것은, 제제에 사용되고 있는 히알루론산의 안정성이나, 피부에 도포한 후의 제제의 히알루론산 및 피부에 존재하고 있던 히알루론산의 안정성에 기여한다고 생각된다. 또한 히알루로니다아제는 염증 효소로서도 알려져, 이 활성을 억제하는 것은 염증을 억제하고, 또한 알레르기에도 억제적으로 작용하는 것이 알려져 있다. 이상과 같은 이유로부터, 피부의 탄력성 및 보습성을 유지하여 주름, 잔주름, 건조하고 거칠음을 막고, 습기가 있는 젊은 피부 상태를 유지하기 위해, 히알루론산 분해 효소인 히알루로니다아제의 유효한 억제제를 개발하는 것이 요구되어 왔다.However, hyaluronic acid having the above-described effect has a high molecular weight and is not easily absorbed into the skin, so it only exerts a moisturizing effect on the skin surface, and does not essentially improve aging skin. In addition, a method of injecting hyaluronic acid directly into the skin is currently being practiced, but its efficacy is limited over time, and skin sagging or chronic inflammation may occur, and a cosmetic composition containing a substance that increases the amount of hyaluronic acid in the skin. Also, although many have been proposed recently, it is the current situation that these have not reached the extent of clearly improving aging skin. The reason why aging skin cannot be improved clearly by external use of hyaluronic acid or by external use of hyaluronic acid production accelerators is presumed to be due to the rapid enzymatic degradation of hyaluronic acid in the skin by hyaluronidase. Has become. Therefore, inhibiting the activity of hyaluronic acid that promotes the decomposition of hyaluronic acid contributes to the stability of hyaluronic acid used in the formulation, hyaluronic acid in the formulation after application to the skin, and the hyaluronic acid present in the skin. I think it does. In addition, hyaluronidase is also known as an inflammatory enzyme, and inhibiting this activity is known to inhibit inflammation and also to inhibit allergy. From the above reasons, we developed an effective inhibitor of hyaluronidase, a hyaluronic acid decomposing enzyme, to prevent wrinkles, fine lines, dry and rough skin by maintaining the skin's elasticity and moisture, and to maintain a youthful skin condition with moisture. It has been required to do.
따라서, 생체에 안전하고, 유효성분이 안정하며, 피부 보습 활성을 지닌 성분의 개발이 절실히 요망되고 있다.Therefore, there is an urgent need to develop a component that is safe for the living body, has a stable active ingredient, and has skin moisturizing activity.
상기의 종래 문제점을 해결하고자, 본 발명은 리보플라빈 5'-포스페이트 나트륨(sodium riboflavin 5'-phosphate)을 유효성분으로 포함하는 화장료 조성물을 제공하고자 한다.In order to solve the above conventional problems, the present invention is to provide a cosmetic composition comprising riboflavin 5'-phosphate as an active ingredient.
또한, 본 발명은 리보플라빈 5'-포스페이트 나트륨을 유효성분으로 포함하는 피부 보습용, 또는 피부 탄력 증진 또는 주름 개선용, 항산화용, 또는 항염증용 화장료 조성물을 제공하고자 한다. In addition, the present invention is to provide a cosmetic composition for skin moisturizing, skin elasticity enhancement or wrinkle improvement, antioxidant, or anti-inflammatory containing riboflavin 5'-phosphate sodium as an active ingredient.
나아가, 본 발명은 리보플라빈 5'-포스페이트 나트륨을 유효성분으로 포함하는 피부 외용제, 의약외품 조성물 또는 건강기능식품 조성물을 제공하고자 한다.Further, the present invention is to provide a skin external preparation, quasi-drug composition, or health functional food composition comprising riboflavin 5'-phosphate sodium as an active ingredient.
상기 목적을 달성하기 위한 하나의 양태로서, 본 발명은 리보플라빈 5'-포스페이트 나트륨(sodium riboflavin 5'-phosphate)을 유효성분으로 포함하는 화장료 조성물을 제공한다.As one aspect for achieving the above object, the present invention provides a cosmetic composition comprising riboflavin 5'-phosphate sodium (sodium riboflavin 5'-phosphate) as an active ingredient.
본 발명의 다른 양태로서, 리보플라빈 5'-포스페이트 나트륨을 유효성분으로 포함하는 피부 보습용 화장료 조성물을 제공한다.As another aspect of the present invention, there is provided a cosmetic composition for moisturizing skin comprising riboflavin 5'-phosphate sodium as an active ingredient.
본 발명의 또 다른 양태로서, 리보플라빈 5'-포스페이트 나트륨을 유효성분으로 포함하는 피부탄력 증진용 또는 주름 개선용 화장료 조성물을 제공한다.In another aspect of the present invention, there is provided a cosmetic composition for enhancing skin elasticity or improving wrinkles, comprising riboflavin 5'-phosphate sodium as an active ingredient.
본 발명의 또 다른 양태로서, 리보플라빈 5'-포스페이트 나트륨을 유효성분으로 포함하는 항산화용 화장료 조성물을 제공한다.As another aspect of the present invention, it provides an antioxidant cosmetic composition comprising riboflavin 5'-phosphate sodium as an active ingredient.
본 발명의 또 다른 양태로서, 리보플라빈 5'-포스페이트 나트륨을 유효성분으로 포함하는 항염증용 화장료 조성물을 제공한다.In another aspect of the present invention, there is provided an anti-inflammatory cosmetic composition comprising riboflavin 5'-phosphate sodium as an active ingredient.
본 발명의 또 다른 양태로서, 리보플라빈 5'-포스페이트 나트륨을 유효성분으로 포함하는 피부 외용제를 제공한다.In another aspect of the present invention, there is provided a skin external preparation comprising riboflavin 5'-phosphate sodium as an active ingredient.
본 발명의 또 다른 양태로서, 리보플라빈 5'-포스페이트 나트륨을 유효성분으로 포함하는 의약외품 조성물을 제공한다.As another aspect of the present invention, it provides a quasi-drug composition comprising riboflavin 5'-phosphate sodium as an active ingredient.
본 발명의 또 다른 양태로서, 리보플라빈 5'-포스페이트 나트륨을 유효성분으로 포함하는 건강기능식품 조성물을 제공한다.As another aspect of the present invention, it provides a health functional food composition comprising riboflavin 5'-phosphate sodium as an active ingredient.
본 발명의 또 다른 양태로서, 리보플라빈 5'-포스페이트 나트륨을 유효성분으로 포함하는, 히알루로니다아제 활성 억제용 조성물을 제공한다.In another aspect of the present invention, it provides a composition for inhibiting hyaluronidase activity, comprising riboflavin 5'-phosphate sodium as an active ingredient.
이하, 본 발명을 보다 상세하게 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명에 있어서, 리보플라빈 5'-포스페이트 나트륨(sodium riboflavin 5'-phosphate)(C17H20N4NaO9P)은 리보플라빈의 유도체 중 하나이다. 상기 리보플라빈 5'-포스페이트 나트륨은 하기 화학식 1로 표시될 수 있다.In the present invention, riboflavin 5'-phosphate sodium (C 17 H 20 N 4 NaO 9 P) is one of riboflavin derivatives. The riboflavin 5'-phosphate sodium may be represented by Formula 1 below.
[화학식 1][Formula 1]
리보플라빈은 플라빈 모노뉴클레오타이드(FMN) 및 플라빈 아데닌 다이뉴클레오타이드(FAD)의 전구체 분자이다. 이들은 생물적 세포 및 유기체에서 다수의 효소적 산화환원 반응을 위한 필수 보조인자이다. 따라서, 리보플라빈은 식품 및 동물 사료 산업에서 중요한 첨가제로 역할할 수 있다.Riboflavin is a precursor molecule of flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD). They are essential cofactors for many enzymatic redox reactions in biological cells and organisms. Thus, riboflavin can serve as an important additive in the food and animal feed industry.
또한, 리보플라빈 5'-포스페이트 나트륨은 결합조직의 세포 간 기저물질인 히알루론산을 가수분해하는 효소인 히알루로니다아제의 활성을 억제함으로써, 히알루론산의 분해, 파괴로 인해 발생되는 문제점을 해결할 수 있다. 히알루론산은 세포 외 기질의 주요성분으로서 수분을 보유하고, 세포 간의 간격을 유지시켜 주며, 세포성장인자와 영양성분의 저장 및 확산에 관여하는 역할을 하므로, 히알루론산의 분해를 막는 것은 피부 건강을 위해서 매우 중요하다. 특히 히알루론산의 구조 및 함량을 유지하는 것은 피부 보습, 피부 탄력 및 주름 개선에 중요한 역할을 한다. In addition, riboflavin 5'-phosphate sodium inhibits the activity of hyaluronidase, an enzyme that hydrolyzes hyaluronic acid, which is a base material between cells of connective tissue, thereby solving problems caused by degradation and destruction of hyaluronic acid. . As hyaluronic acid is a major component of the extracellular matrix, it retains moisture, maintains the space between cells, and plays a role in the storage and diffusion of cell growth factors and nutrients. Therefore, preventing the decomposition of hyaluronic acid affects skin health. It is very important for you. In particular, maintaining the structure and content of hyaluronic acid plays an important role in skin moisturizing, skin elasticity and wrinkle improvement.
구체적으로, 히알루로니다아제의 활성을 억제함으로써, 히알루론산의 함량 감소로 인한 피부의 수분 함유량 감소 및 피부 건조, 피부 탄력 저하 및 피부 주름 증가, 피부 처짐, 만성 염증 발생, 알레르기 발생, 피부 조직의 붕괴 등의 문제를 해결 또는 개선할 수 있다. Specifically, by inhibiting the activity of hyaluronidase, the moisture content of the skin decreases due to the decrease in the content of hyaluronic acid and the skin is dry, the skin elasticity decreases and the skin wrinkles increase, the skin sagging, chronic inflammation occurs, allergies occur, Problems such as collapse can be solved or improved.
그에 따라, 본 발명의 리보플라빈 5'-포스페이트 나트륨을 유효성분으로 포함하는 화장료 조성물은 피부 보습용, 또는 피부 탄력 증진 또는 주름 개선용 화장료 조성물일 수 있다.Accordingly, the cosmetic composition comprising the riboflavin 5'-phosphate sodium of the present invention as an active ingredient may be a cosmetic composition for moisturizing the skin or improving skin elasticity or wrinkles.
본 발명에 있어서, "피부 보습"이란 피부에 수분감을 증가시켜주고, 촉촉한 상태를 유지시키는 것을 의미한다. 피부 보습 효과는 피부의 주름개선, 탄력도 증가에 도움을 줄 수 있다. In the present invention, "skin moisturizing" means to increase the moisture sensation on the skin and maintain a moist state. The skin moisturizing effect can help improve skin wrinkles and increase elasticity.
또한, "피부 탄력 증진"이란 피부가 쳐지거나 늘어지는 정도를 완화시켜주는 것으로, 엘라스틴으로 구성된 탄력섬유가 콜라겐(collagen)이라고 하는 교원섬유와 함께 존재하는데, 엘라스틴과 콜라겐이 충분히 존재하는 상태에서 피부 탄력이 유지되는 것을 말한다. 본 발명에 있어서, "주름 개선"이란 피부에 주름이 생성되는 것을 억제 또는 저해하거나, 이미 생성된 주름을 완화시키는 것을 말한다.In addition, "improving skin elasticity" is to alleviate the degree of sagging or sagging of the skin, and elastic fibers composed of elastin exist together with collagen fibers called collagen. In the state where elastin and collagen are sufficiently present, the skin It means that the elasticity is maintained. In the present invention, "wrinkle improvement" refers to suppressing or inhibiting the generation of wrinkles on the skin or alleviating wrinkles that have already been generated.
본 발명의 일실시예에서는 리보플라빈 5'-포스페이트 나트륨의 히알루로니다아제 저해 활성을 확인함으로써, 리보플라빈 5'-포스페이트 나트륨이 피부 보습, 피부 탄력 증진 또는 주름 개선에 대한 효과가 우수함을 확인하였으며, 추가로 패널 테스트를 통해 피부 주름 개선 및 탄력 증진 효과를 확인하였다.In one embodiment of the present invention, by confirming the hyaluronidase inhibitory activity of riboflavin 5'-phosphate sodium, it was confirmed that riboflavin 5'-phosphate sodium has excellent effects on moisturizing skin, enhancing skin elasticity, or improving wrinkles. Through a low-panel test, the effect of improving skin wrinkles and enhancing elasticity was confirmed.
또한, 본 발명의 리보플라빈 5'-포스페이트 나트륨을 유효성분으로 포함하는 화장료 조성물은 항산화용 또는 항염증용 화장료 조성물일 수 있다. 항산화 및 항염증 활성 등을 통하여 피부 트러블 개선에도 효과가 있을 수 있다. 본 발명의 일실시예에서는 리보플라빈 5'-포스페이트 나트륨의 DPPH 라디칼 소거 활성을 통해 항산화 활성을, iNOS 활성 억제를 통해 항염증 활성을 확인하였다.In addition, the cosmetic composition comprising the
본 발명에서, 유효성분인 리보플라빈 5'-포스페이트 나트륨은 화장료 조성물 총 중량 기준으로 0.0001 중량% 내지 10 중량% 포함될 수 있다. 리보플라빈 5'-포스페이트 나트륨 함량이 0.0001 중량% 미만일 경우 히알루로니다아제 저해 활성을 기대하기 어렵고, 10 중량%를 초과하는 경우 증가하는 함유량만큼 뚜렷한 효과가 기대되지 않을 수 있다.In the present invention, riboflavin 5'-phosphate sodium, which is an active ingredient, may be included in an amount of 0.0001% to 10% by weight based on the total weight of the cosmetic composition. When the riboflavin 5'-phosphate sodium content is less than 0.0001% by weight, it is difficult to expect hyaluronidase inhibitory activity, and when it exceeds 10% by weight, a distinct effect may not be expected as much as the increasing content.
본 발명에 따른 화장료 조성물은 용액, 외용연고, 크림, 폼, 영양화장수, 유연화장수, 팩, 유연수, 유액, 메이크업베이스, 에센스, 비누, 액체 세정료, 입욕제, 선 스크린크림, 선오일, 현탁액, 유탁액, 페이스트, 겔, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션, 패취 및 스프레이로 구성된 군으로부터 선택되는 제형으로 제조할 수 있으나, 이에 제한되는 것은 아니다.The cosmetic composition according to the present invention is a solution, external ointment, cream, foam, nutrient lotion, soft lotion, pack, softening water, emulsion, makeup base, essence, soap, liquid cleaning agent, bathing agent, sunscreen cream, sun oil, suspension, Emulsion, paste, gel, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, can be prepared in a formulation selected from the group consisting of a patch and spray, but limited thereto. It is not.
또한, 본 발명의 화장료 조성물은 일반 피부 화장료에 배합되는 화장품학적으로 허용 가능한 담체를 1 종 이상 추가로 포함할 수 있으며, 통상의 성분으로 예를 들면 유분, 물, 계면활성제, 보습제, 저급 알콜, 증점제, 킬레이트제, 색소, 방부제, 향료 등을 적절히 배합할 수 있으나, 이에 제한되는 것은 아니다.In addition, the cosmetic composition of the present invention may additionally contain one or more cosmetically acceptable carriers that are blended in general skin cosmetics, and as common ingredients, for example, oil, water, surfactant, moisturizer, lower alcohol, A thickener, a chelating agent, a colorant, a preservative, a fragrance, and the like may be appropriately mixed, but the present invention is not limited thereto.
본 발명의 화장료 조성물에 포함되는 화장품학적으로 허용 가능한 담체는 제형에 따라 다양하다.The cosmetically acceptable carrier included in the cosmetic composition of the present invention varies depending on the formulation.
본 발명의 제형이 연고, 페이스트, 크림 또는 젤인 경우에는, 담체 성분으로서 동물성 유, 식물성 유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크, 산화아연 또는 이들의 혼합물이 이용될 수 있다.When the formulation of the present invention is an ointment, paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide or Mixtures of these can be used.
본 발명의 제형이 파우더 또는 스프레이인 경우에는, 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록사이드, 칼슘 실케이트, 폴리아미드 파우더 또는 이들의 혼합물이 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진제를 포함할 수 있다.When the formulation of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder, or mixtures thereof may be used as a carrier component, and in particular, in the case of a spray, additional chloro Propellants such as fluorohydrocarbon, propane/butane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는, 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되며, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알콜, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일이 이용될 수 있으며, 특히, 목화씨 오일, 땅콩 오일, 옥수수 배종 오일, 올리브오일, 피마자 오일 및 참깨 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 이용될 수 있다.When the formulation of the present invention is a solution or emulsion, a solvent, a solubilizing agent or an emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil may be used, and in particular, cottonseed oil, peanut oil, corn seed oil, olive oil, castor oil and sesame oil, glycerol aliphatic ester, polyethylene glycol or fatty acid ester of sorbitan may be used. have.
본 발명의 제형이 현탁액인 경우에는, 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알콜, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, an ethoxylated isostearyl alcohol, a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, micro Crystalline cellulose, aluminum metahydroxide, bentonite, agar or tracant, and the like may be used.
본 발명의 제형이 비누인 경우에는 담체 성분으로서 지방산의 알칼리 금속 염, 지방산 헤미에스테르 염, 지방산 단백질 히드롤리제이트, 이세티오네이트, 라놀린 유도체, 지방족 알콜, 식물성 유, 글리세롤, 당 등이 이용될 수 있다.When the formulation of the present invention is a soap, an alkali metal salt of a fatty acid, a fatty acid hemiester salt, a fatty acid protein hydrolyzate, isethionate, a lanolin derivative, an aliphatic alcohol, vegetable oil, glycerol, sugar, etc. may be used as a carrier component. I can.
본 발명의 다른 양태로서, 본 발명은 리보플라빈 5'-포스페이트 나트륨을 유효성분으로 포함하는 피부 외용제 조성물을 제공할 수 있다. 상기 조성물은 피부 보습용, 피부 탄력 증진용 또는 주름 개선용, 항산화용, 또는 항염증용 피부 외용제 조성물일 수 있다.As another aspect of the present invention, the present invention can provide a composition for external application for skin comprising riboflavin 5'-phosphate sodium as an active ingredient. The composition may be a composition for external application for skin for moisturizing skin, for enhancing skin elasticity or for improving wrinkles, for antioxidant, or for anti-inflammatory.
본 발명에 있어서, "외용제"는 외용으로 제공되는 제제로 외용산제, 외용정제, 외용액제, 연고제, 경고제, 좌제 등이 있다. 외용제제란 아연화(亞鉛華)전분 등, 피부점막의 미란(爛), 궤양 등에 산포하는 것을 의미하고, 외용정제는 용해정 또는 질정을 의미하며, 외용액제는 물, 에타놀, 유류 등을 용매로 하는 액상제제이고, 양치질, 습포, 세척, 점안, 점비(点鼻) 등에 사용한다. 또한, 연고제는 피부에 바르는 적당한 조도의 반고형제, 경고는 상온고형, 체온으로 연화하는 피부적용제이고, 좌제는 항문, 질, 요도에 적용하는 제제이다.In the present invention, "external preparations" are preparations provided for external use and include external powders, tablets for external use, liquids for external use, ointments, warnings, suppositories, and the like. External preparation means zincized starch, erosion of the skin mucous membrane, ulcers, etc. It is a liquid preparation made from, and is used for brushing teeth, poultice, washing, eye drops, and nasal drops. In addition, ointment is a semi-solid formulation of moderate roughness applied to the skin, warning is a skin application that softens at room temperature and body temperature, and suppositories are a formulation applied to the anus, vagina and urethra.
"피부 외용제"는 외용제 중에서도 피부 외용에 작용하는 제제를 의미하는 것으로 본 발명에서는 상기 화장료 조성물을 유효성분으로 함유함으로써 피부 보습에 탁월한 효과를 가지는 피부 외용제를 의미한다. 구체적으로, 피부 외용제에는 크림, 젤, 패취, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 또는 카타플라스마제의 피부 외용제 형태의 의약품 또는 의약외품으로 제조하여 사용할 수 있으나, 이에 제한되지 않는다."External preparation for skin" means a preparation that acts on the external application of the skin among external preparations, and in the present invention, it means a preparation for external application for skin having an excellent effect on skin moisturizing by containing the cosmetic composition as an active ingredient. Specifically, for external preparations for skin, creams, gels, patches, sprays, ointments, warnings, lotions, liniment, pasta, or cataplasma may be prepared and used as drugs or quasi-drugs for skin external use, but are not limited thereto. Does not.
본 발명의 또 다른 양태로서, 본 발명은 리보플라빈 5'-포스페이트 나트륨 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 의약외품 조성물을 제공할 수 있다. 상기 조성물은 피부 보습용, 피부 탄력 증진용 또는 주름 개선용, 항산화용, 또는 항염증용 의약외품 조성물일 수 있다. As another aspect of the present invention, the present invention can provide a quasi-drug composition comprising riboflavin 5'-phosphate sodium or a pharmaceutically acceptable salt thereof as an active ingredient. The composition may be a quasi-drug composition for skin moisturizing, skin elasticity or wrinkle improvement, antioxidant, or anti-inflammatory.
본 발명의 의약외품 조성물에는 상기 성분 외에 필요에 따라 약학적으로 허용 가능한 담체, 부형제 또는 희석제를 더욱 포함할 수 있다. 상기 약학적으로 허용 가능한 담체, 부형제 또는 희석제는 본 발명의 효과를 해하지 않는 한 제한되지 않으며, 예를 들어 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제, 윤활제, 감미제, 방향제, 보존제 등을 포함할 수 있다.The quasi-drug composition of the present invention may further include a pharmaceutically acceptable carrier, excipient, or diluent as needed in addition to the above ingredients. The pharmaceutically acceptable carrier, excipient, or diluent is not limited as long as it does not impair the effects of the present invention, for example, fillers, extenders, binders, wetting agents, disintegrants, surfactants, lubricants, sweeteners, fragrances, preservatives, etc. Can include.
본 발명의 약학적으로 허용 가능한 담체, 부형제 또는 희석제의 대표적인 예로는, 락토즈, 덱스트로스, 슈크로스, 솔비톨, 만니톨, 자일리톨, 말티톨, 전분, 젤라틴, 글리세린, 아카시아 고무, 알지네이트, 칼슘포스페이트, 칼슘카보네이트, 칼슘실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로즈, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트, 광물유, 프로필렌글리콜, 폴리에틸렌글리콜, 식물성 오일, 주사가능한 에스테르, 위텝솔, 마크로골, 트윈 61, 카카오지, 라우리지 등을 들 수 있다.Representative examples of the pharmaceutically acceptable carrier, excipient or diluent of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, maltitol, starch, gelatin, glycerin, gum acacia, alginate, calcium phosphate, calcium Carbonate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, propylene glycol, polyethylene glycol, vegetable oil , Injectable esters, Witepsol, Macrogol, Tween 61, cacao butter, and laurage.
본 발명의 의약외품 조성물은 소독 청결제, 샤워폼, 연고액, 물티슈, 코팅제 등을 예시할 수 있으나 이에 제한되는 것이 아니며, 의약외품의 제제화 방법, 용량, 이용방법, 구성성분 등은 기술분야에 공지된 통상의 기술로부터 적절히 선택될 수 있다.The quasi-drug composition of the present invention may exemplify a disinfectant cleaner, a shower foam, an ointment, a wet tissue, a coating agent, etc., but is not limited thereto, and the formulation method, dosage, usage method, component, etc. of quasi-drugs are known in the art. It can be appropriately selected from the techniques of.
본 발명의 또 다른 양태로서, 본 발명은 리보플라빈 5'-포스페이트 나트륨을 유효성분으로 포함하는 건강기능식품 조성물을 제공할 수 있다. 상기 조성물은 피부 보습용, 피부 탄력 증진용 또는 주름 개선용, 항산화용, 또는 항염증용 건강기능식품 조성물일 수 있다.As another aspect of the present invention, the present invention can provide a health functional food composition comprising riboflavin 5'-phosphate sodium as an active ingredient. The composition may be a health functional food composition for skin moisturizing, skin elasticity enhancement or wrinkle improvement, antioxidant, or anti-inflammatory.
본 발명에 있어서, "건강기능식품"이란 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 정제, 캅셀, 분말, 과립, 액상 및 환 등의 형태로 제조 및 가공한 식품을 말한다. 여기서 "기능성"이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건용도에 유용한 효과를 얻는 것을 의미한다. 본 발명의 건강기능식품은 당업계에서 통상적으로 사용되는 방법에 의하여 제조 가능하며, 상기 제조시에는 당업계에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다. 또한 상기 건강기능식품의 제형 또한 건강기능식품으로 인정되는 제형이면 제한 없이 제조될 수 있다. 본 발명의 식품 조성물은 다양한 형태의 제형으로 제조될 수 있으며, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고, 휴대성이 뛰어나, 본 발명의 건강기능식품은 피부 탄력 증진 또는 주름 개선 효과를 증진시키기 위한 보조제로 섭취가 가능하다.In the present invention, "health functional food" refers to food manufactured and processed in the form of tablets, capsules, powders, granules, liquids and pills using raw materials or ingredients having useful functions for the human body. Here, the term "functionality" means obtaining a useful effect for health purposes such as controlling nutrients or physiological effects on the structure and function of the human body. The health functional food of the present invention can be prepared by a method commonly used in the art, and at the time of manufacture, it can be prepared by adding raw materials and ingredients commonly added in the art. In addition, the formulation of the health functional food may be prepared without limitation as long as it is a formulation recognized as a health functional food. The food composition of the present invention can be prepared in various forms of formulation, and unlike general drugs, it has the advantage of not having side effects that may occur when taking the drug for a long time using food as a raw material, and is excellent in portability. Health functional foods can be consumed as a supplement to improve skin elasticity or wrinkle improvement.
본 발명의 건강기능식품이 취할 수 있는 형태에는 제한이 없으며, 통상적인 의미의 식품을 모두 포함할 수 있고, 기능성 식품 등 당업계에 알려진 용어와 혼용 가능하다. 아울러 본 발명의 건강기능식품은 당업자의 선택에 따라 식품에 포함될 수 있는 적절한 기타 보조성분과 공지의 첨가제를 혼합하여 제조할 수 있다. 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 쵸코렛, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 본 발명에 따른 화학식 1로 표시되는 화합물을 주성분으로 하여 제조한 즙, 차, 젤리 및 주스 등에 첨가하여 제조할 수 있다. 또한 동물을 위한 사료로 이용되는 식품도 포함한다.There is no limitation on the form that the health functional food of the present invention can take, and may include all foods in the usual sense, and may be mixed with terms known in the art such as functional foods. In addition, the health functional food of the present invention can be prepared by mixing suitable other auxiliary ingredients and known additives that may be included in the food according to the choice of a person skilled in the art. Examples of foods that can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and There are vitamin complexes and the like, and can be prepared by adding to juice, tea, jelly, juice, etc. prepared using the compound represented by Formula 1 according to the present invention as a main component. It also includes foods used as feed for animals.
한편, 본 발명은 화합물인 리보플라빈 5'-포스페이트 나트륨 또는 이를 포함하는 조성물을 개체의 피부에 도포하는 단계를 포함하여, 피부 보습, 항산화, 항염증, 피부탄력 증진 또는 주름 개선 방법에 사용될 수 있다. 상기 개체는 쥐, 가축, 인간 등을 포함하는 포유동물을 제한 없이 포함한다.On the other hand, the present invention can be used in a method for skin moisturizing, antioxidant, anti-inflammatory, skin elasticity enhancement or wrinkle improvement, including the step of applying a compound riboflavin 5'-phosphate sodium or a composition containing the same to the skin of an individual. The subject includes, without limitation, mammals including mice, livestock, humans, and the like.
본 발명의 또 다른 양태로서, 본 발명은 리보플라빈 5'-포스페이트 나트륨을 유효성분으로, 히알루로니다아제 활성 억제용 조성물을 제공할 수 있다. 리보플라빈 5'-포스페이트 나트륨은 히알루론산을 가수분해하는 효소인 히알루로니다아제의 활성을 억제함으로써, 히알루론산의 분해 및 파괴를 방지할 수 있으며, 그로 인해 피부 보습, 피부 탄력 및 주름 개선을 할 수 있다.As another aspect of the present invention, the present invention can provide a composition for inhibiting hyaluronidase activity, using riboflavin 5'-phosphate sodium as an active ingredient. Riboflavin 5'-phosphate sodium inhibits the activity of hyaluronidase, an enzyme that hydrolyzes hyaluronic acid, thereby preventing the decomposition and destruction of hyaluronic acid, thereby moisturizing the skin, improving skin elasticity and wrinkles. have.
본 발명의 조성물은 리보플라빈 5'-포스페이트 나트륨을 유효성분으로 포함함으로써, 히알루로니다아제의 활성을 억제하여 히알루론산의 분해를 방지할 수 있으며, 피부 보습, 피부 탄력 증진 또는 주름 개선 효과를 가진다. 또한, 피부 조직의 붕괴를 막고 알레르기 발생을 방지할 수 있으며, 항산화 또는 항염증 효과를 가진다.The composition of the present invention contains riboflavin 5'-phosphate sodium as an active ingredient, thereby inhibiting the activity of hyaluronidase to prevent the decomposition of hyaluronic acid, and has an effect of moisturizing the skin, enhancing skin elasticity or improving wrinkles. In addition, it can prevent the breakdown of the skin tissue and prevent the occurrence of allergies, and has an antioxidant or anti-inflammatory effect.
또한, 본 발명의 리보플라빈 5'-포스페이트 나트륨을 포함하는 조성물은 피부 외용제, 의약외품 조성물 또는 건강기능식품 조성물로 사용할 수 있다.In addition, the composition containing riboflavin 5'-phosphate sodium of the present invention can be used as an external preparation for skin, a quasi-drug composition, or a health functional food composition.
도 1은 일 실시예에 따라 인체유래 피부 섬유아세포에 리보플라빈 5'-포스페이트 나트륨을 처리한 농도에 따른 세포 증식률을 실험한 결과를 나타낸 것이다.
도 2는 일 실시예에 따른 리보플라빈 5'-포스페이트 나트륨의 히알루로니다아제 저해 활성 정도를 나타낸 것이다. FIG. 1 shows the results of testing the cell proliferation rate according to the concentration of human-derived skin fibroblasts treated with riboflavin 5'-phosphate sodium according to an embodiment.
Figure 2 shows the degree of hyaluronidase inhibitory activity of riboflavin 5'-phosphate sodium according to an embodiment.
이하, 실시예를 통하여 본 발명을 보다 상세히 설명하고자 한다. 이들 실시예는 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail through examples. These examples are for explaining the present invention more specifically, and the scope of the present invention is not limited to these examples.
실험예 1: 리보플라빈 5'-포스페이트 나트륨의 세포 독성 확인Experimental Example 1: Confirmation of cytotoxicity of riboflavin 5'-phosphate sodium
인체유래 피부 섬유아세포 (HaCaT) 의 세포 생존능을 저해하지 않는 리보플라빈 5'-포스페이트 나트륨의 농도를 확인하기 위하여 다음과 같은 세포 독성 실험을 우선적으로 수행하였다. 피부 섬유아세포를 96-well microplate 에 5×103 세포/웰의 농도로 접종하고, 37℃, 5% 농도의 CO2 배양기에서 24시간 동안 배양하였다. 그 다음, 배지를 제거하고 10%의 혈청이 함유된 배양 배지(DMEM) 에 리보플라빈 5'-포스페이트 나트륨을 각 농도별 (12.5 ppm, 25 ppm, 50 ppm, 100 ppm)로 첨가하고 세포에 처리하여 24 시간 동안 배양하였다.In order to confirm the concentration of riboflavin 5'-phosphate sodium, which does not inhibit the cell viability of human skin fibroblasts (HaCaT), the following cytotoxicity experiments were performed preferentially. Skin fibroblasts were inoculated in a 96-well microplate at a concentration of 5×10 3 cells/well, and cultured for 24 hours in a CO 2 incubator at 37°C and 5% concentration. Then, the medium was removed, riboflavin 5'-phosphate sodium was added at each concentration (12.5 ppm, 25 ppm, 50 ppm, 100 ppm) to the culture medium (DMEM) containing 10% serum, and treated to the cells. Incubated for 24 hours.
세포 독성 측정은 세포 증식 정도를 관찰할 수 있는 CCK-8(Cell Counting Kit-8, DOJINDO Laboratories)을 이용하여 다음과 같이 수행하였다. 리보플라빈 5'-포스페이트 나트륨을 농도 별로 처리한 96-well plate 에 CCK-8 용액을 10㎕씩 첨가하여 37℃, 5% CO2 배양기에 1시간 30분 동안 배양한 후 분광광도계를 이용하여 450nm에서 흡광도를 측정하였다. 세포 증식률은 리보플라빈 5'-포스페이트 나트륨이 처리되지 않은 미처리군 대비 각 농도별 처리군의 흡광도 비율로 계산하고 하기 표 1과 도 1에 나타내었다.Cytotoxicity measurement was performed as follows using CCK-8 (Cell Counting Kit-8, DOJINDO Laboratories), which can observe the degree of cell proliferation. After adding 10 µl of CCK-8 solution to a 96-well plate treated with riboflavin 5'-phosphate sodium by concentration, incubating for 1 hour and 30 minutes in a 37°C, 5% CO 2 incubator at 450 nm using a spectrophotometer. The absorbance was measured. The cell proliferation rate was calculated as the absorbance ratio of the treated group at each concentration compared to the untreated group not treated with riboflavin 5'-phosphate sodium, and is shown in Table 1 and FIG. 1 below.
그 결과, 배양배지에 리보플라빈 5'-포스페이트 나트륨을 12.5 ppm, 25 ppm, 50 ppm, 및 100 ppm로 처리한 경우에도 세포가 정상적으로 잘 증식하였으며, 이로부터 5'-포스페이트 나트륨이 세포에 대한 독성을 갖지 않으며 안전함을 확인할 수 있었다.As a result, even when the culture medium was treated with riboflavin 5'-phosphate sodium 12.5 ppm, 25 ppm, 50 ppm, and 100 ppm, the cells proliferated normally, from which sodium 5'-phosphate showed toxicity to cells. It did not have, and it was confirmed that it was safe.
실험예 2: 리보플라빈 5’-포스페이트 나트륨의 히알루로니다아제 저해 활성Experimental Example 2: Hyaluronidase inhibitory activity of riboflavin 5'-phosphate sodium
50 mL의 히알루로니다아제 (1 ng/mL) (R&D systems; 7358-GH-020)을 마이크로 튜브에 넣고, 평가 약제 50 mL 를 가하여 25℃ 에서 1시간 인큐베이트 하였다. 평가 약제로서, 리보플라빈 5'-포스페이트 나트륨(Sigma-aldrich; R7774)과 리보플라빈(Sigma-aldrich; R9504)을 이용하고, 효과의 비교를 위하여 아무것도 첨가하지 않은 미처리군(비교군)과, 양성 대조군으로 Gallotannin (Santa Cruz Biotechnology; sc-202619) 을 가하였다. 리보플라빈 5'-포스페이트 나트륨과 리보플라빈은 첨가 후의 농도가 각각 12.5 ppm, 25 ppm, 50 ppm, 100 ppm 이 되도록 첨가하였고, Gallotannin 은 850 ppm이 되도록 첨가하였다. 인큐베이션 후 히알루로니다아제 활성 ELISA (Hyaluronidase Activity ELISA, Echelon; K-6000)로 각 농도에서 히알루로니다아제의 활성에 의해 분해되고 남아있는 히알루론산의 양을 분광광도계를 이용하여 450 nm에서 측정하였다. 미처리군(비교군)의 히알루로니다아제의 활성을 100으로 한 결과를 하기 표 2와 도 2에 도시하였다. 50 mL of hyaluronidase (1 ng/mL) (R&D systems; 7358-GH-020) was placed in a microtube, 50 mL of an evaluation agent was added, and incubated at 25°C for 1 hour. As an evaluation drug, riboflavin 5'-phosphate sodium (Sigma-aldrich; R7774) and riboflavin (Sigma-aldrich; R9504) were used, and for the comparison of the effects, the untreated group (comparative group) and a positive control group were Gallotannin (Santa Cruz Biotechnology; sc-202619) was added. Riboflavin 5'-phosphate sodium and riboflavin were added so that the concentrations after addition were 12.5 ppm, 25 ppm, 50 ppm, and 100 ppm, respectively, and Gallotannin was added to 850 ppm. After incubation, hyaluronidase activity ELISA (Echelon; K-6000) was decomposed by the activity of hyaluronidase at each concentration and the amount of remaining hyaluronic acid was measured at 450 nm using a spectrophotometer. . The results of setting the hyaluronidase activity of the untreated group (comparative group) to 100 are shown in Table 2 below and FIG. 2.
상기 표 2와 도 2에 나타낸 바와 같이, 양성대조군인 gallotannin은 90% 이상 히알루로니다아제의 활성을 억제하였으며, 리보플라빈 5'-포스페이트 나트륨은 농도 의존적으로 히알루로니다아제의 활성을 순차적으로 저해하였다. 특히, 리보플라빈 5'-포스페이트 나트륨은 매우 적은 양으로도 히알루로니다아제의 활성을 효과적으로 저해하였으며, 구체적으로 5ppm인 경우에는 약 30%의 히알루로니다아제 활성을 억제, 10ppm인 경우에는 약 65%의 활성을 억제하였으며, 20ppm인 경우에는 90% 이상의 활성을 억제하여 양성대조군인 gallotannin 850 ppm 과 동등한 수준으로 활성을 억제하였다. As shown in Table 2 and FIG. 2, gallotannin, a positive control, inhibited the activity of hyaluronidase by 90% or more, and riboflavin 5'-phosphate sodium sequentially inhibited the activity of hyaluronidase in a concentration-dependent manner. . In particular, riboflavin 5'-phosphate sodium effectively inhibited the activity of hyaluronidase even in a very small amount, specifically inhibiting about 30% hyaluronidase activity in the case of 5 ppm, and about 65% in the case of 10 ppm. In the case of 20 ppm, more than 90% of the activity was suppressed, and the activity was suppressed at the same level as the positive control gallotannin 850 ppm.
또한, 리보플라빈 5'-포스페이트 나트륨의 히알루로니다아제 저해 활성은 농도에 상관없이 리보플라빈의 히알루로니다아제 억제 활성 보다 현저히 높게 나타났다.In addition, the hyaluronidase inhibitory activity of riboflavin 5'-phosphate sodium was significantly higher than the hyaluronidase inhibitory activity of riboflavin regardless of the concentration.
실험예 3: 리보플라빈 5'-포스페이트 나트륨의 α-α-Diphenyl-β-picrylhydrazyl (DPPH) 라디칼 소거 활성Experimental Example 3: α-α-Diphenyl-β-picrylhydrazyl (DPPH) radical scavenging activity of riboflavin 5'-phosphate sodium
99% 에탄올에 리보플라빈 5'-포스페이트 나트륨을 녹여 5, 50, 100 μg/mL의 농도가 되도록 희석하였다. 각각의 희석액 800μL에, 99% 메탄올에 녹인 0.15 mM DPPH 용액 200 μL를 가하고 실온에 30분간 방치한 뒤, 517 nm에서 흡광도를 측정하였고, 3번 이상 실험을 반복하여 결과를 얻었다. 이때 리보플라빈 5'-포스페이트 나트륨의 자유라디칼 소거 활성 비교를 위하여, 천연 항산화제인 L-아스코르브산(L-ascorbic acid)을 사용하여 DPPH 라디칼의 소거활성을 측정하여 하기 표 3에 나타내었다.Riboflavin 5'-phosphate sodium was dissolved in 99% ethanol and diluted to a concentration of 5, 50, and 100 μg/mL. To 800 μL of each dilution, 200 μL of a 0.15 mM DPPH solution dissolved in 99% methanol was added and allowed to stand at room temperature for 30 minutes, and the absorbance was measured at 517 nm, and the experiment was repeated three or more times to obtain results. At this time, in order to compare the free radical scavenging activity of riboflavin 5'-phosphate sodium, the scavenging activity of DPPH radicals was measured using L-ascorbic acid, a natural antioxidant, and is shown in Table 3 below.
(Scavenging effect)Elimination effect (%)
(Scavenging effect)
그 결과, 리보플라빈 5'-포스페이트 나트륨은 5, 50 또는 100 ppm의 농도에서 각각 4.12, 15.01, 67.16 %의 DPPH 라디칼 저해활성을 보였고, 양성대조군으로 사용된 아스코르브산(ascorbic acid)은 0.5 또는 1 ppm의 농도에서 각각 약 18.81, 56.39% 의 DPPH 라디칼 저해활성을 보였다. 즉, 본 발명의 리보플라빈 5'-포스페이트 나트륨은 우수한 항산화 활성을 가짐을 확인하였다.As a result, riboflavin 5'-phosphate sodium showed 4.12, 15.01, 67.16% DPPH radical inhibitory activity at concentrations of 5, 50, or 100 ppm, respectively, and ascorbic acid used as a positive control was 0.5 or 1 ppm. DPPH radical inhibitory activity was shown at the concentration of about 18.81 and 56.39%, respectively. That is, it was confirmed that the riboflavin 5'-phosphate sodium of the present invention has excellent antioxidant activity.
실험예 4: 리보플라빈 5'-포스페이트 나트륨의 항염증 활성Experimental Example 4: Anti-inflammatory activity of riboflavin 5'-phosphate sodium
염증상태에서 활성화된 iNOS에 의해 생성된 NO는 병리적인 혈관확장, 세포독성, 조직손상 등과 같은 생체에 유해한 작용을 나타낸다. 리보플라빈 5'-포스페이트 나트륨의 항염증 효능을 NO의 양 측정 및 iNOS(inducible nitric oxide synthase) 분석을 이용하여 확인하였다. RAW 264.7 세포를 DMEM 배지를 이용하여 12시간 동안 배양 후, 리보플라빈 5'-포스페이트 나트륨 5, 10, 20 ppm 과 LPS(1μg/ml)를 동시에 함유한 새로운 배지에 처리 처리하여 24시간 배양하였다. 이렇게 배양된 샘플들로부터 세포배양액 중에 존재하는 NO의 양을 ELISA 리더를 이용하여 540nm에서 흡광도를 측정하였고, standard curve는 DMSO를 연속 희석한 결과를 이용하였으며, 생성된 NO의 양과 iNOS 활성도를 평가하여 그 결과를 표 4에 나타냈다. 또한, 음성대조군(Negative control)과 아스피린을 사용한 양성대조군(Positive control)으로 항염증 활성을 비교하였으며, 사용한 아스피린은 약 5 ppm농도에서 iNOS 활성을 50% 억제하였다. NO produced by iNOS activated in the inflammatory state exhibits harmful effects on the living body such as pathological vasodilation, cytotoxicity, and tissue damage. The anti-inflammatory efficacy of riboflavin 5'-phosphate sodium was confirmed by measuring the amount of NO and analyzing inducible nitric oxide synthase (iNOS). RAW 264.7 cells were cultured in DMEM medium for 12 hours, and then treated with a new medium containing 5, 10, 20 ppm riboflavin 5'-phosphate sodium and LPS (1 μg/ml) at the same time and cultured for 24 hours. The amount of NO present in the cell culture solution from the cultured samples was measured at 540 nm using an ELISA reader, and the standard curve was the result of serial dilution of DMSO, and the amount of NO produced and the iNOS activity were evaluated. The results are shown in Table 4. In addition, anti-inflammatory activity was compared with the negative control group and the positive control group using aspirin, and the used aspirin inhibited iNOS activity by 50% at a concentration of about 5 ppm.
그 결과, 표 4에 나타낸 바와 같이, 리보플라빈 5'-포스페이트 나트륨은 LPS로 유도된 RAW 264.7 세포에서 iNOS에 대한 억제효과를 나타내며, 이는 농도의존적이라는 점도 확인할 수 있었다.As a result, as shown in Table 4, riboflavin 5'-phosphate sodium showed an inhibitory effect on iNOS in LPS-induced RAW 264.7 cells, and it was also confirmed that it was concentration dependent.
제조예: 크림 제조Manufacturing example: cream manufacturing
하기 표 5의 조성과 같이, 리보플라빈 5'-포스페이트 나트륨을 포함하는 크림을 통상의 방법으로 제조하였다. 또한, 유효성분을 제외한 나머지 성분으로 제조한 크림을 비교예로 제조하였다.As shown in the composition in Table 5 below, a cream containing riboflavin 5'-phosphate sodium was prepared by a conventional method. In addition, a cream prepared with the remaining ingredients excluding the active ingredient was prepared as a comparative example.
실험예 5: 패널 테스트를 통한 피부 주름 개선 효과 확인Experimental Example 5: Confirmation of skin wrinkle improvement effect through panel test
상기 제조예와 비교예의 크림에 대해서 건강한 35세에서 50세의 여성을 대상으로 피부 주름 개선 효과를 다음과 같이 시험하였다.For the creams of Preparation Example and Comparative Example, the effect of improving skin wrinkles was tested for healthy 35 to 50 year old women as follows.
35세에서 50세까지의 여성 30명을 15명씩 2개의 군으로 구분하고 1군은 리보플라빈 5'-포스페이트 나트륨을 1 중량% 포함하는 제조예의 크림을, 2군은 비교예의 크림을 안면부에 1일 1회 3개월간 도포하였다. 3개월 후 피부 주름의 개선 정도를 피험자의 설문 및 피부 주름의 영상 분석을 통해 평가하였다. 피험자의 설문은 피부 주름 개선 및 탄력 증진에 관하여 사용 전과 비교하여 개선 없음, 약간의 개선, 상당한 개선의 3단계로 판정하였으며, 그 결과는 하기 표 6에 나타내었다.30 women aged 35 to 50 years old were divided into two groups of 15 each, group 1 was prepared with the cream of the preparation example containing 1% by weight of riboflavin 5'-phosphate sodium, and the group 2 was given the cream of the comparative example on the face for 1 day. It was applied once for 3 months. After 3 months, the degree of improvement of skin wrinkles was evaluated through a questionnaire of subjects and image analysis of skin wrinkles. The subject's questionnaire was evaluated in three stages of no improvement, slight improvement, and significant improvement in terms of skin wrinkle improvement and elasticity improvement compared to before use, and the results are shown in Table 6 below.
상기 표 6에서 볼 수 있듯이, 리보플라빈 5'-포스페이트 나트륨을 포함한 제조예의 크림을 사용한 경우, 사용하지 않은 비교예의 크림을 사용한 경우 보다 피부 주름 개선 효과가 우수함을 확인할 수 있다.As can be seen in Table 6, it can be seen that when the cream of Preparation Example containing riboflavin 5'-phosphate sodium was used, the effect of improving skin wrinkles was superior to that of using the cream of Comparative Example not used.
이상의 설명으로부터, 본 발명이 속하는 기술분야의 당업자는 본 발명이 그 기술적 사상이나 필수적 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 이와 관련하여, 이상에서 기술한 실시 예들은 모든 면에서 예시적인 것이며 한정적인 것이 아닌 것으로서 이해해야만 한다. 본 발명의 범위는 상기 상세한 설명보다는 후술하는 특허 청구범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.From the above description, those skilled in the art will understand that the present invention can be implemented in other specific forms without changing the technical spirit or essential features. In this regard, the embodiments described above are illustrative in all respects and should be understood as non-limiting. The scope of the present invention should be construed that all changes or modifications derived from the meaning and scope of the claims to be described later rather than the above detailed description, and equivalent concepts thereof, are included in the scope of the present invention.
Claims (12)
Riboflavin 5'-phosphate sodium (sodium riboflavin 5'-phosphate) containing as an active ingredient, skin antioxidant cosmetic composition.
The cosmetic composition of claim 1, wherein the content of the riboflavin 5'-phosphate sodium is 0.0001% to 10% by weight based on the total weight of the cosmetic composition.
The cosmetic composition of claim 1, wherein the cosmetic composition further comprises a cosmetically acceptable carrier.
4. Sunscreen cream, sun oil, suspension, emulsion, paste, gel, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, patch, and spray selected from the group consisting of That is formulated into a dosage form, a cosmetic composition.
Riboflavin 5'- containing sodium phosphate as an active ingredient, skin antioxidant health functional food composition.
A quasi-drug composition for skin antioxidant containing riboflavin 5'-phosphate sodium as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200040464A KR102184154B1 (en) | 2020-04-02 | 2020-04-02 | Composition for anti-oxidation comprising sodium riboflavin 5'-phosphate as an active ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200040464A KR102184154B1 (en) | 2020-04-02 | 2020-04-02 | Composition for anti-oxidation comprising sodium riboflavin 5'-phosphate as an active ingredient |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170037744A Division KR102098927B1 (en) | 2017-03-24 | 2017-03-24 | cosmetic composition comprising sodium riboflavin 5'-phosphate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200038225A KR20200038225A (en) | 2020-04-10 |
| KR102184154B1 true KR102184154B1 (en) | 2020-11-27 |
Family
ID=70291853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020200040464A KR102184154B1 (en) | 2020-04-02 | 2020-04-02 | Composition for anti-oxidation comprising sodium riboflavin 5'-phosphate as an active ingredient |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102184154B1 (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63188627A (en) * | 1987-01-31 | 1988-08-04 | Rooto Seiyaku Kk | Antiallergic and antiphlogistic agents |
| JP3202810B2 (en) * | 1992-10-15 | 2001-08-27 | 協和醗酵工業株式会社 | Cosmetics |
-
2020
- 2020-04-02 KR KR1020200040464A patent/KR102184154B1/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200038225A (en) | 2020-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102144568B1 (en) | Composition for skin conditioning comprising Morus alba L. extract | |
| KR20200097673A (en) | Composition for improving skin troubles comprising mortierella oil as an active ingredient | |
| KR20170078270A (en) | Composition for improving skin conditions comprising Ethyl ferulate | |
| KR102184154B1 (en) | Composition for anti-oxidation comprising sodium riboflavin 5'-phosphate as an active ingredient | |
| KR102098927B1 (en) | cosmetic composition comprising sodium riboflavin 5'-phosphate | |
| KR20180090123A (en) | Composition for skin improvement containing liquidambaric lactone | |
| KR20180027213A (en) | Composition for skin improvement containing Salvianolic acid C | |
| KR20180045626A (en) | Composition for skin improvement containing valechlorine | |
| KR20170078259A (en) | Composition for improving skin conditions comprising Isosteviol | |
| KR20140072419A (en) | Anti-Wrinkle Composition | |
| KR20180061663A (en) | Composition for skin improvement containing dehydroevodiamine | |
| KR20180061662A (en) | Composition for skin improvement containing anemoside A3 | |
| KR102644106B1 (en) | Composition for skin improvement containing corytuberine | |
| KR20180032029A (en) | Composition for skin improvement containing diosbulbin B | |
| KR102662255B1 (en) | Composition for skin improvement containing sinigrin | |
| KR20170136801A (en) | Composition for improving skin conditions | |
| KR102662257B1 (en) | Composition for skin improvement containing rebaudioside C | |
| KR102662256B1 (en) | Composition for skin improvement containing Syringaresnol-4-O-β-D-apiofuranosy | |
| KR20170078360A (en) | Composition for improving skin conditions comprising Periplogenin | |
| KR102628373B1 (en) | Composition for skin improvement containing dracorhodin perochlorate | |
| KR102644107B1 (en) | Composition for skin improvement containing vomicine | |
| KR20170078351A (en) | Composition for improving skin conditions comprising hastatoside | |
| KR20170076351A (en) | Composition for improving skin conditions comprising bruceine D | |
| KR20170076429A (en) | Composition for improving skin conditions comprising Polygalasaponin F | |
| KR20170076487A (en) | Composition for improving skin conditions comprising caudatin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |